

## THE DISTILLERY

## This week in therapeutics

| Indication      | Target/marker/<br>pathway                 | Summary   | Licensing<br>status                               | Publication and contact<br>information  |
|-----------------|---|---|---|---|
| Cardiovascular  | disease                                   |   |   |   |
| Marfan syndrome | Angiotensin II type 1<br>receptor (AGTR1) | Studies in mice suggest that angiotensin receptor<br>blockers (ARBs) could help treat aortic aneurysm<br>associated with Marfan syndrome. In a mouse model<br>of Marfan syndrome, a generic ARB decreased aortic<br>root growth compared with vehicle. Next steps include<br>an investigator-initiated Phase III trial of the generic<br>ARB losartan to treat Marfan syndrome–associated<br>aneurysm. At least six generic ARBs are marketed to<br>treat hypertension. | Unpatented;<br>licensing status<br>not applicable | Habashi, J.P. <i>et al. Science</i> ;<br>published online April 15, 2011;<br>doi:10.1126/science.1192152<br><b>Contact:</b> Harry C. Dietz,<br>The Johns Hopkins University School of<br>Medicine, Baltimore, Md.<br>e-mail:<br>hdietz@jhmi.edu |
|                 |   | SciBX 4(17); doi:10.1038/scibx.2011.482   |   |   |

Published online April 28, 2011